Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.62 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.58 |
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793003 | 1.00 | PTPN12 (0.62) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7484742 | 0.99 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7484734 | 0.99 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7489851 | 0.99 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7489859 | 0.99 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL6885016 | 0.97 | PTPN12 (0.64) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL6885013 | 0.97 | PTPN12 (0.64) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7487680 | 0.93 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7487682 | 0.93 | PTPN12 (0.61) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL7495526 | 0.93 | PTPN12 (0.66) | PTPN12PTPN22AKR1B1PTPN1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192143-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000076987-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1192143-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076987-A1 | RHODANINE DERIVATIVES FOR USE IN A METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | APP, PSEN1, PSEN2 | PTPN12 4871/4885PTPN22 4833/4885AKR1B1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.